STOCK TITAN

AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
conferences
Rhea-AI Summary
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced that David O’Toole, CFO, will present at TD Cowen’s 44th Annual Health Care Conference. The presentation will be available via live audio webcast on March 5, 2024, at 9:50 a.m. ET. A replay will be accessible on the company's website for 90 days post-event.
Positive
  • None.
Negative
  • None.

VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O’Toole, Chief Financial Officer, will present at TD Cowen’s 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 9:50 a.m. Eastern Time.

A live audio webcast of the presentation will be available under the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com. A replay of the webcast will be available at the same location for approximately 90 days following the conclusion of the event.

About AVITA Medical, Inc.
AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, in the United States.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.


David O’Toole will present at the conference on March 5, 2024, at 9:50 a.m. Eastern Time.

The live audio webcast will be available on AVITA Medical's website at https://ir.avitamedical.com.

The replay of the webcast will be accessible at the same location for approximately 90 days after the event.
AVITA Medical Inc

NASDAQ:RCEL

RCEL Rankings

RCEL Latest News

RCEL Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Medical Specialties
US
Valencia

About RCEL

avita medical (http://www.avitamedical.com/) is a publicly listed regenerative medicine company trading on the australian stock exchange (asx:avh) and otc markets (otcqx:avmxy). the company’s lead product, recell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. recell is patented, ce-marked for europe, tga- registered in australia, and sfda-cleared in china. recell is not available for sale in the united states; in the us recell is an investigational device limited by federal law to investigational use.